2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3942 Comprehensive genomic profiling of treatment-Naïve and relapsed Waldenström macroglobulinemia patients using a targeted NGS assay

Tina Bagratuni, PhD, Konstantinos Giatras2, Christos Vlachos, PhD3, Ioannis Kollias4, Eleni Kalafati5, Christine-Ivy Liacos, PhD6, Alexandra Papadimou7, Konstantina Taouxi8, Katerina Chrisostomidou9, Agisilaos Papadopoulos10, Foteini Theodorakakou, MD11, Maria Gavriatopoulou, MD12, Evangelos Terpos, MD13, Meletios-Athanasios (Thanos) C. Dimopoulos, MD14, Efstathios Kastritis, MD15
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 National and Kapodistrian University of Athens, Athens, Greece
13 National and Kapodistrian University of Athens, Athens, Greece
14 National and Kapodistrian University of Athens, Athens, Greece
15 National and Kapodistrian University of Athens, Athens, Greece

The genomic profiling of Waldenström macroglobulinemia (WM) has been focusing on screening for MYD88 and CXCR4 mutations, the two principal genomic biomarkers used for disease prognostication and therapeutic decision-making. While this targeted approach has significantly advanced the molecular characterization of WM, it provides only a limited view of the disease's genomic landscape. Comprehensive targeted sequencing is therefore needed to identify additional recurrent genetic alterations, improve molecular subclassification, and better define the genomic determinants of disease progression and treatment response. We evaluated the performance of a WM/lymphoid custom-designed targeted next-generation sequencing (NGS, LymphUOA) assay for comprehensive genomic profiling of treatment-naïve (NDWM) and relapsed WM (RRWM) patients and determine its clinical utility for improving molecular stratification beyond conventional MYD88 and CXCR4 screening.

We analyzed 154 bone marrow (BM) aspirate samples from 134 NDWM and RRWM patients, using the LymphUOA panel (Twist Bioscience) designed to detect single nucleotide variations and insertions/deletions in 72 genes after CD19 enrichment. The average sequencing depth was 360x across samples. Libraries were sequenced on an Illumina miSeq100 platform. Sequencing reads were aligned to the human reference genome (hg38) and variants were called by MuTect2.

The cohort of 134 WM patients included 116 ND patients of which 35 IgM-MGUS, 27 asymptomatic WM (aWM), 54 newly diagnosed symptomatic WM (sWM) and 36 relapsed WM patients. Furthermore, matched BM samples from 18 patients at diagnosis and relapse were also collected for this analysis. At diagnosis, at least one variant was observed in 105 out of 116 patients (90%), 2 genetic alterations in 71%, 3 alterations in 54% and over 4 alterations in 15% of patients. The median number of genomic alterations was 1 (range: 0–4) in the IgM-MGUS group, 2 (range: 0–8) in the aWM group, and 4 (range 0–11) in the sWM group. The most frequently mutated genes in the ND cohort were MYD88 (82%), followed by IGLL5 (15%), KMT2D (16%), ATM (14%), CXCR (13%) and ARID1A (8%). TP53 gene was mutated in 5% of newly diagnosed patients (1 aWM and 4 sWM).

In the RRWM arm (n=36), the most frequently mutated genes were MYD88 (88%), CXCR4 (33%), IGLL5 (33%), KMT2D (27%), TP53 (24%), ARID1A (18%) and KMT2C (12%). Less frequently mutated genes included TRRAP (9%) and TET2 (6%), while ARID1B and FAT3 were identified in 6 and 9% of RRWM patients, respectively. These patients had been previously treated with chemoimmunotherapy (Dexamethasone–Rituximab–Cyclophosphamide, 35%), Bendamustine–Rituximab (BR, 6%), Ofatumumab–Fludarabine–Cyclophosphamide (OFC, 20%), Ixazomib–Rituximab–Dexamethasone (IRD, 6%), covalent BTKi (Ibrutinib or Zanubrutinib, 12%).  Comparison of genomic alterations between NDWM and RRWM revealed significant increases in the frequencies of CXCR4 (p = 0.0129), TP53 (p = 0.0033), and KMT2D (p = 0.0095) in RRWM with the median number of genomic events in this group being 5 (range: 2–10).

In longitudinal samples from WM patients collected at diagnosis and at relapse, we observed an overall increase in genomic alterations at relapse in 57% of patients (8/14) compared with their matched diagnostic samples. TP53 variants were acquired at the time of relapse in 4 of 18 patients (22%), whereas one patient harbored TP53 variations at both time points. These patients had received DRC as first-line therapy. Additionally, several KMT2D alterations were identified exclusively at the time of relapse (21%, 3 out of 18 patients) while were absent from the samples at diagnosis, suggesting the emergence or expansion of KMT2D-mutant subclones during disease progression. Furthermore, one patient acquired a BTK mutation at relapse following treatment with ibrutinib, consistent with the emergence of BTK-mediated resistance.

Our findings demonstrate that the genomic landscape of WM evolves throughout disease progression, with relapsed patients exhibiting a higher mutational burden and increased frequencies of TP53 and KMT2D alterations. The acquisition of relapse-specific mutations highlights the dynamic nature of clonal evolution and underscores the potential value of longitudinal genomic profiling for identifying mechanisms of treatment resistance. The clinical impact of these acquired mutations needs further evaluation.

Tina Bagratuni, PhD: No relevant conflicts of interest to declare.